Wave Life Sciences Initiates Phase 2A Combination Trial Of WVE-007 (GalNAc-siRNA) With Tirzepatide For Obesity - WVE News | RalliesWave Life Sciences Initiates Phase 2A Combination Trial Of WVE-007 (GalNAc-siRNA) With Tirzepatide For Obesity
W
WVE• Phase 2A obesity combination trial
- Wave Life Sciences Ltd. said it has initiated a Phase 2A combination trial of WVE-007 (GalNAc-siRNA) with tirzepatide for obesity.
- The company said a maintenance trial of WVE-007 is expected to start in the second half of 2026.
•
